Gadodiamide is a gadolinium-based contrast agent for diagnostic magnetic resonance imaging (MRI) indicated for intravenous use to: 

• Visualize lesions with abnormal vascularity in the brain, spine, and associated tissues 
• Facilitate the visualization of lesions with abnormal vascularity within the thoracic, abdominal, pelvic cavities, and the retroperitoneal space 

MRI

CNS :Adults and Pediatrics; 2-16 years of age: 0.2 mL/kg (0.1 mmol/kg) 

Body: Adults and Pediatrics; 2-16 years of age:

• Kidney: 0.1 mL/kg (0.05 mmol/kg)
• Intrathoracic, intra-abdominal, and pelvic cavities: 0.2 mL/kg (0.1 mmol/kg) 

Most Common Adverse Reactions:

• Headache
• Nausea
• Dizziness
• Injection site reactions (e.g., pain, warmth, and burning sensation)

Serious or life-threatening reactions include: cardiac failure, arrhythmia and myocardial infarction.

Headache

Nausea

Dizziness

Arrhythmia

• Inadvertent intrathecal use of Gadodiamide has caused convulsions, coma, sensory and motor neurologic deficits.

• Nephrogenic Systemic Fibrosis (NSF):

  • Gadodiamide may increase the risk of NSF in patients with impaired renal function. Assess renal function before administration.

• Hypersensitivity Reactions:

  • Anaphylactic and anaphylactoid reactions, sometimes fatal, have been reported. Administer a test dose in patients with a history of allergy.

• Renal Impairment:

  • Gadodiamide is contraindicated in patients with acute kidney injury or chronic severe renal impairment.

• Pregnancy and Lactation:

  • Use Gadodiamide during pregnancy only if the potential benefit justifies the potential risk to the fetus.